GPN › analyze
GPN · Analyze from before
Date: 2026-08-27 | Price: $92.74 | Baseline: 2026-06-04 (analyze, conviction 7.5, verdict INITIATE 2-3%) at $64.50
Second-newest prior: 2026-04-28 (analyze, conviction 6.5, verdict WATCH) at $68.33
1. What this updates
A portfolio-specific passage was removed from the public build.
Event list since June 4: - Q1 FY26 GAAP results (already known to baseline) restated in fuller context — the $1.79B H1 2026 net loss is now visible in full: $1.69B of it is a one-time discontinued-operations loss on the Issuer Solutions divestiture, not an operating problem. Operating results from continuing operations were positive throughout (confirmed via GPN's own Q2 press release). - Q2 FY26 print, Aug 5-8 2026 — adjusted EPS $3.46 (+12% YoY), adjusted net revenue $3.16B (+4% normalized). FY2026 adjusted EPS guidance CUT to $13.60-13.80 (was $13.80-14.00), attributed to a ~100bp Middle East conflict / travel-portfolio headwind management now expects to persist through year-end. Margin-expansion guide (150bp) unchanged. - Net leverage moved from 2.9x (Q1) to "just below 3.5x" (Q2) — CFO Josh Whipple, Q2 earnings call — the opposite direction from the baseline's "ahead of schedule" reading, and sitting almost exactly on the baseline's own stated thesis-break level ("net leverage rises above 3.5x"). - 11 sell-side price-target raises since June 3 (Wolfe $111→$125, Truist $79→$95, RBC $96→$102, TD Cowen $74→$90, UBS $80→$91, Argus $95→$110, Barclays $81→$89, KBW $76→$95, Goldman $82→$94) plus one upgrade (Morgan Stanley, Equal-Weight→Overweight, PT $65→$100, July 20). Only Wells Fargo trimmed (PT $105→$95, still Overweight). Mean target now $103, median $95 — both now close to spot rather than 40-60% above it. - Genius platform metrics refreshed: bookings +25% QoQ (same cadence as baseline), new Genius locations +50% YoY, new-customer yields +75% YoY (new figure, not in baseline). - Worldpay synergy story bifurcated: the $600M cost-synergy target is on pace (~$300M of integration cost spent through H1); a $200M revenue-synergy target is now disclosed for the first time, explicitly weighted to 2027-2028, not near-term. - No dividend change — still $0.25/quarter, flat.
2. The delta ledger
Lead with the two RETRACTED/SUPERSEDED rows that carry the real news, then the rest.
| # | Claim (baseline) | Type | Status | What moved it |
|---|---|---|---|---|
| 5 | Net leverage 2.9x at Q1 2026, "ahead of the 3.0x target," covenant headroom ample | State | ❌ RETRACTED | CFO stated Q2 leverage ended "just below 3.5x." The direction reversed — it rose, not fell. This is a single primary source (the CFO on the earnings call) but it is the most authoritative source available and directly contradicts the baseline's own framing. Sits almost exactly at the baseline's self-declared break level. |
| 14 | ROIC distorted by goodwill; FCF/EV yield ~6.5% legacy, ~12.9% pro forma combined — "exceptional" | Trend | 🔄 SUPERSEDED | Reconstructing TTM FCF from the four reported quarters (Q3'25 $599M + Q4'25 $347M + Q1'26 −$550M + Q2'26 $427M) = $822.7M TTM FCF against a $43.6B EV = 1.9% FCF/EV yield — a fraction of the touted 12.9%. Annualizing Q2 alone (the first "clean" post-close quarter) gives a more representative ~$1.7B run-rate, 3.9% yield — still well short of the $4B combined-entity target that anchored the original valuation case. The gap is plausibly transition cost (integration spend, deal-related working-capital swings) rather than a structural break, but it is unproven either way this pass. |
| 8 | Forward P/E 4.6-4.9x — "the market is pricing near-certain failure" | Price | 🔄 SUPERSEDED | Two things moved it, not one. (a) Price is up 43.8%. (b) The multiple itself was on the wrong fiscal year. Yahoo's forwardPE (5.79x today) prices epsForward ($16.02) — that is FY2027 consensus. The correct FY2026 (current-year, matches guidance) multiple is priceEpsCurrentYear = 6.78x, using epsCurrentYear $13.68 ≈ the guide midpoint. This is [[pitfall-vendor-forward-eps-is-the-wrong-fiscal-year]] firing again — the error direction is the usual one (manufactures a false bargain). GPN is still cheap on adjusted earnings vs. payments peers (10-20x), just not as cheap as either report claimed. |
| 6 | FY2026 adj. EPS guidance $13.80-14.00, reaffirmed May 6 | State | 🔁 REFRESHED | Cut to $13.60-13.80 at the Aug print — the first negative guidance revision since the deal closed. Company attributes it entirely to the Middle East conflict's travel-volume drag (100bp), not execution. Margin-expansion guide (150bp) held. |
| 20 | Worldpay synergy delivery — $600M cost target, execution credibility open question (from 4/28 report) | Structural | 🔁 REFRESHED | Cost synergies on pace. But a new, separate $200M revenue-synergy target surfaced this quarter, explicitly weighted to 2027-2028 — later and smaller than the near-term cross-sell momentum (Subway, KFC, CKE) implied. Splits what the baseline treated as one story into two: cost synergies delivering now, revenue synergies deferred. |
| 15 | Goodwill+intangibles $25.5B on $17.6B market cap | State | 🔁 REFRESHED | Now $26.98B goodwill + $19.41B intangibles = $46.4B on a $24.5B market cap (full Worldpay consolidation). Tangible book value is now −$23.3B (was +$1.58B pre-close) — Graham's tangible-book variant is no longer computable in any useful sense. |
| 9 | Fair value $100-150 base / $180-250 bull / $55-70 bear | Price | 🔄 SUPERSEDED | Re-derived from scratch (§6). New base case is lower and narrower: $95-130. |
| 10/22 | Conviction 7.5, INITIATE 2-3% at $62-70, thesis break $55 | Judgment | 🔄 SUPERSEDED | Adjudicated last, §4. |
| 1 | Post-transformation GPN: ~80% merchant pure-play, $3.7T volume, 175 countries | Structural | ✅ CARRIED | Q2 revenue $3.32B confirms full Worldpay consolidation; no change to the structural description. |
| 2 | Genius platform is the moat-widening bet (Subway, KFC/Pizza Hut, CKE) | Structural | ✅ CARRIED, reinforced | Bookings +25% QoQ (same pace as baseline), plus two new metrics: locations +50% YoY, customer yields +75% YoY. |
| 12 | Moat rating: wide-moderate (scale + switching costs structural; Genius still building) | Structural | ✅ CARRIED | Standing prior on structural claims; nothing this pass overturns it. |
| 13 | Adyen/Stripe cloud-native architecture is the most credible competitive threat | Structural | ⏳ UNTESTED | No new competitive-intelligence gathered this pass; carried forward on the standing prior, not re-verified. |
| 16 | Risk trigger: thesis breaks if Genius bookings go flat 2 quarters | Judgment | ✅ CARRIED — risk did not fire | A predicted risk that failed to materialize is itself a force in the moat's favor, per protocol. |
| 18 | Risk trigger: re-evaluate if organic growth falls below 3% | Judgment | ✅ CARRIED — risk did not fire | Q2 normalized growth 4% (with the 100bp ME drag baked in); FY guide 4-5%. Softer than the >5.5% Q1 print but still above the trigger. |
| 21 | $600M cost-synergy target intact | Structural | ✅ CARRIED | ~$300M of integration cost spent through H1, tracking to plan. |
| 11 | June 3 drop was a sell-side model-trimming artifact, not fundamental deterioration | State | ✅ CARRIED, strongly | The strongest-corroborated row in this ledger: 11 independent PT raises plus a rating upgrade since. Multiple, independent (different desks, not one feed repeating) confirmation. |
| 4 | Buybacks/capital return ~14% share-count decline (3yr), $7.5B/$2B+ 2026 target | Trend | ✅ CARRIED | $1.2B returned YTD, ~50% of the $2B+ full-year plan, on pace at midyear. |
| 19 | Dividend well covered, ~1.5% yield, flat/non-growth | Trend | ✅ CARRIED | Still $0.25/qtr flat. Yield now 1.08% (price-driven, not a dividend cut). Coverage on adjusted EPS remains ample (~7% payout). |
| 3 | FCF 3yr CAGR 7.8% (legacy); combined-entity FCF target ~$4B | Trend | 📉 DRIFTED | H1 2026 actual FCF is negative $123M (Q1 −$550M, Q2 +$427M) — the deal-transition quarter dragged the half deeply negative. Not yet disproving the $4B combined target (management still guides $2B+ capital returns funded partly from balance-sheet cash), but two quarters of actual results run well behind it. Breaks if Q3 FCF does not clearly recover toward the Q2 run-rate or better. |
| 7 | Q1 2026 beat: adj. EPS $2.96 vs $2.85 | State | ✅ CARRIED | Historical fact, unchanged. |
3. How the close calls were decided
Leverage (claim 5) vs. the qualitative integration story (claims 2, 20, 21). These pull in opposite directions and both are real. The Genius/cost-synergy evidence is broader and more corroborated (multiple metrics, a full earnings call of specifics) than the leverage figure (one CFO statement, no independent cross-check obtained this pass — GPN does not file a 10-Q line labeled "net leverage," it is a company-defined, EBITDA-adjusted metric). I did not retract the Genius/integration claims on the strength of the leverage move, and I did not let the leverage move get diluted by the good integration news — they are different claims about different things (execution quality vs. balance-sheet risk) and a strong quarter on one does not offset a bad reading on the other. Where I could not reconcile leverage independently — a back-of-envelope check using TTM normalized EBITDA ($3.54B) against net debt ($18.15B) implies ~5.1x, well above the company's own "just below 3.5x" — I flagged the gap rather than picking a number. The company's metric likely uses a forward/pro-forma EBITDA base (including assumed synergies) that a trailing GAAP-normalized calc will not replicate; this is not resolved and should not be treated as resolved.
FCF drift (claim 3/14) vs. Q1's known one-time character. The Q1 2026 cash-flow statement is saturated with deal mechanics — $7.36B business-sale proceeds, $13.6B debt repaid, $5.3B debt issued, ~$300M of the disclosed integration-cost budget — all in one quarter. It would be wrong to read Q1's −$550M FCF as a clean signal of anything. But it would be equally wrong to wave it away: operating cash flow itself (before capex) was negative $289M in Q1, which is not explained by financing-line noise. I weighted this as DRIFTED, not RETRACTED — the $4B target is not disproven, but it has gone two quarters without support and one of those quarters was actively negative on an operating basis.
The vendor forward-P/E correction (claim 8) is additive to, not a substitute for, the price move. Both facts move the same claim in the same direction (less cheap than baseline believed), and I recorded both rather than crediting either alone with the full effect.
4. Thesis persistence and conviction delta
Structural + Trend claims: 9 total (1, 2, 3, 4, 12, 13, 14, 19, 20). Survived as CARRIED/REFRESHED: 6 (1, 2, 4, 19, 20, and 12 counted under moat standing-prior). DRIFTED: 1 (3). SUPERSEDED: 1 (14). UNTESTED: 1 (13).
Thesis persistence: ~67%. High enough to say the business-model and execution thesis is substantially intact — Genius traction, integration milestones, and the sell-side re-rating are real and corroborated. Not high enough to say nothing changed: the two claims that did not survive (leverage direction, FCF/EV yield) were specifically the claims the original valuation case leaned on hardest for the "extraordinary, near-failure-priced" framing. A thesis can hold on the business and still lose its valuation edge — that is closer to what happened here than a broken company.
Conviction: 7.5 → 6.5. Driven by, in order of weight: 1. Net leverage claim reversed and now sits at the baseline's own stated break level (claim 5) — largest single driver. 2. FCF run-rate materially behind both the legacy trend and the combined-entity target, with one outright negative-OCF quarter (claim 3/14) — second-largest driver. 3. Price is up 43.8% with the entry zone unreachable, and the corrected forward multiple removes part of the "priced for failure" framing that justified an aggressive initiate (claim 8) — compresses margin of safety independent of the other two. 4. Partially offset by: the guidance cut was modest (100bp), clearly attributed to a named geopolitical cause rather than execution, and every other named baseline risk (Genius churn, organic growth <3%, integration credibility) did not fire — the qualitative case is, if anything, stronger than in June.
The downgrade is a valuation-and-balance-sheet call, not a business-quality call — worth saying plainly, per the framework's own instruction to distinguish thesis safety from other kinds of safety.
5. What is genuinely new
- The $200M revenue-synergy target and its 2027-2028 timing — not disclosed in either prior report. It reframes "Worldpay synergies" as two separate programs on two separate clocks.
- New Genius metrics (locations +50% YoY, customer yields +75% YoY) not present in the baseline.
- A second, independent vendor-data trap found on this name: Yahoo's headline
freeCashflowfield reads $7.87B TTM — reconstructing from the four quarterly cash-flow statements gives $822.7M. A 9.6x error, in the direction that (again) manufactures a false bargain if quoted uncritically. This is the CLAUDE.md TTM-sum guard firing exactly as warned, on a field distinct from the forward-EPS trap. Worth apitfall-*note (see below). - The Wells Fargo trim (PT $105→$95, July 9) is the lone dissent inside an otherwise unanimous round of upside revisions — worth naming since it is the only sell-side voice moving against the grain during this window, even though it remains Overweight.
6. Updated verdict
A portfolio-specific passage was removed from the public build.
Valuation, re-derived from scratch
| Model | Basis | Fair value | Weight |
|---|---|---|---|
| Forward P/E (current-FY, corrected) | 6.78x actual vs. 8-10x base peer-normalized target, $13.70 guide midpoint | $110-137 | 40% |
| FCF multiple | 12-15x on normalized (Q2-annualized) run-rate FCF/share ~$6.45 — not the unproven $4B combined target | $77-97 | 40% |
| Bogle expected return (3-5yr) | 1.08% yield + 11-13% EPS growth ± limited further re-rating (most of the multiple expansion already happened this year) | ~13-15%/yr, NPV ~$120-135 | 15% |
| Graham's Number | Unreliable — tangible book now deeply negative; GAAP-continuing EPS ($2.11) vs. reported BVPS ($86.94) spans $64-164 depending on EPS basis used | not weighted meaningfully | 5% |
Fair value range: $95-130 base. (Was $100-150 in the baseline — narrower and lower, driven by weighting the FCF read as heavily as the earnings read, per the framework's own First Principle that FCF is harder to fake than earnings.) Bull case (synergies land on both cost and revenue tracks, leverage resumes falling): $150-175. Bear case (leverage keeps rising, Q3 FCF stays weak, another guidance cut): $65-80.
Entry zone: $78-88 (replaces the unreachable $62-70). Trim: 10x fwd (current-fiscal-year
basis — implies ~$137 at the $13.70 guide midpoint; do not let this be computed off Yahoo's raw
forwardPE field without checking it against the guide, since that field is on FY2027 for this
name, not FY2026).
Thesis break, restated and sharpened from the baseline's $55 (now unreachable and stale): - Net leverage confirmed still rising, or above 3.5x, at the Q3 print. - Q3 FCF fails to clearly exceed the Q2 $427M quarterly run-rate. - A second consecutive guidance cut, for any reason.
Upgrade conditions: - Q3 leverage resumes falling (back toward 3.0x or below). - Q3 FCF confirms a clean recovery (>$500M quarterly, no deal-related noise). - Revenue-synergy program shows any 2026/early-2027 pull-forward evidence, ahead of the disclosed 2027-2028 schedule.
A portfolio-specific passage was removed from the public build.
7. What this pass did NOT test
- Claim 13 (Adyen/Stripe competitive threat) — UNTESTED. No fresh competitive intelligence gathered this pass; carried on the moat standing-prior only. This is the second consecutive pass in which the specific competitive-threat claim was not independently re-verified (the June 4 report also did not update it beyond the April framing) — worth flagging as a claim that keeps deferring.
- The exact leverage-metric definition is unresolved. Company-stated "just below 3.5x" vs. a back-of-envelope 5.1x using TTM normalized EBITDA are not reconciled. Needs the 10-Q's explicit covenant-EBITDA definition, which was not pulled this pass.
- Whether the Q1 2026 negative operating cash flow was purely deal-related or partly structural is asserted from management's own framing (integration cost spend), not independently verified against a working-capital breakdown in the 10-Q.
- Single-source risk on the leverage figure — one CFO statement on one earnings call, no independent analyst note or filing cross-check obtained. If this number turns out to be mis-transcribed or context-dependent, claim 5's RETRACTED status should be revisited first.
Sources: GPN Q2 2026 press release (investors.globalpayments.com) | Q2 2026 earnings call transcript (Motley Fool, Aug 8 2026) | Yahoo Finance MCP: get_stock_info, quarterly income/balance sheet/cash-flow statements, upgrades/downgrades, insider transactions | python .mcp/fin.py GPN --news | WebSearch: Q2 2026 guidance, net leverage, Worldpay synergies, Genius metrics | Baseline reports: Output/Stocks/Fintech/GPN/analyze-2026-06-04.md, analyze-2026-04-28.md